Overview
CHICAGO AND WASHINGTON, D.C. (July 2, 2014) — A cross-disciplinary group of McDermott partners from the Firm’s Corporate, Health, Intellectual Property and Antitrust/Competition practice groups have joined together with the American Health Lawyers Association (AHLA) to produce a timely, in-depth resource for those following the changing life sciences legal landscape.
“The Fundamentals of Life Sciences Law: Drugs, Devices, and Biotech, Second Edition,” provides a solid grounding in the legal principles and issues inherent in this complex area. Both new practitioners and experienced attorneys alike will benefit from the book’s in-depth coverage of important legal issues.
This new edition, overseen by McDermott partner Kristian Werling in his role as Editor in Chief, features contributions from other McDermott partners and some of the most experienced and respected practitioners of life sciences and health law. Specifically, McDermott Corporate partner Richard B. Smith, and McDermott Intellectual Property, Transactions & Strategy partner Judith Toffenetti each contributed chapters to the new book. Editorial assistance was provided by McDermott partners Jeffrey Brennan, Nicole Castle, Carla Hine and Jennifer Geetter. Among the topics covered are:
- Regulation of Drugs, Medical Devices and Diagnostics
- Clinical Trials
- Fraud and Abuse
- Federal Agencies
- Regulation of Advertising, and Promotion of Drugs, Medical Devices, and Biologics
- Antitrust
- Privacy
- State Regulation
- Intellectual Property
- Payment and Reimbursement
- International Issues
- Life Sciences Licensing Transactions
“Whether you are looking for an overview of key legal issues in this industry, or you need a go-to reference on your shelf, ‘The Fundamentals of Life Sciences Law’ is meant to provide a solid grounding in the legal principles and issues inherent in this complex area,” said Mr. Werling who serves as one of the leaders of McDermott’s life sciences transactional practice. “Both new practitioners and experienced attorneys alike will benefit from the knowledge we have gathered here.”
With an over 30-year history of serving the health care industry, McDermott Will & Emery has one of the largest and most prestigious health practice groups in the world. The Firm’s international health team, resident in the Firm’s Boston, Chicago, Los Angeles, Miami, Munich, New York, Rome, Silicon Valley and Washington, D.C. offices, counsels leading organizations in every major sector of the health and life sciences industry on regulatory and business transaction issues. McDermott is the only law firm to receive Tier 1 rankings in health care nationally by all of the industry’s top legal directories: Chambers USA, The Legal 500 USA, U.S. News–Best Lawyers and Law360. For the fifth consecutive year, Chambers USA ranked the Firm’s health practice as the only firm in Tier 1 in the United States (2010–2014).
McDermott Will & Emery’s Life Sciences Industry Group has over 135 professionals, of which 60 have advanced science degrees and many others with government and industry experience, working in 18 offices around the world. With insights drawn from the leading health practice and a global reach, McDermott provides its clients with integrated business solutions, bringing the required experience from its leading transactional, tax, health, intellectual property, antitrust and regulatory practices to solve the challenges and leverage the opportunities facing its clients.
About McDermott Will & Emery
McDermott Will & Emery is a premier international law firm with a diversified business practice. Numbering more than 1,100 lawyers, we have offices in Boston, Brussels, Chicago, Düsseldorf, Frankfurt, Houston, London, Los Angeles, Miami, Milan, Munich, New York, Orange County, Paris, Rome, Seoul, Silicon Valley and Washington, D.C. Further extending our reach into Asia, we have a strategic alliance with MWE China Law Offices in Shanghai.
